Big pharma shares shelved compounds
This article was originally published in Scrip
Executive Summary
Seven big pharma companies have made available to academic researchers a collection of 68 "deprioritized" drug compounds through their partnership with the UK's Medical Research Council. UK-based scientists will be allowed to apply for MRC funding to use any of the compounds in studies investigating the underlying mechanics of disease.